| Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of … S Slavin, A Nagler, E Naparstek, Y Kapelushnik, M Aker, G Cividalli, ... Blood, The Journal of the American Society of Hematology 91 (3), 756-763, 1998 | 2651 | 1998 |
| Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4 A Peled, I Petit, O Kollet, M Magid, T Ponomaryov, T Byk, A Nagler, ... Science 283 (5403), 845-848, 1999 | 2128 | 1999 |
| G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4 I Petit, M Szyper-Kravitz, A Nagler, M Lahav, A Peled, L Habler, ... Nature immunology 3 (7), 687-694, 2002 | 1770 | 2002 |
| The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in transendothelial/stromal migration and … A Peled, O Kollet, T Ponomaryov, I Petit, S Franitza, V Grabovsky, ... Blood, The Journal of the American Society of Hematology 95 (11), 3289-3296, 2000 | 1004 | 2000 |
| Comparative studies of human FcRIII-positive and negative natural killer cells. A Nagler, LL Lanier, S Cwirla, JH Phillips Journal of immunology (Baltimore, Md.: 1950) 143 (10), 3183-3191, 1989 | 915 | 1989 |
| Autologous transplantation and maintenance therapy in multiple myeloma A Palumbo, F Cavallo, F Gay, F Di Raimondo, D Ben Yehuda, MT Petrucci, ... New England Journal of Medicine 371 (10), 895-905, 2014 | 894 | 2014 |
| HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver O Kollet, S Shivtiel, YQ Chen, J Suriawinata, SN Thung, MD Dabeva, ... The Journal of clinical investigation 112 (2), 160-169, 2003 | 888 | 2003 |
| Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies R Berger, R Rotem-Yehudar, G Slama, S Landes, A Kneller, M Leiba, ... Clinical Cancer Research 14 (10), 3044-3051, 2008 | 877 | 2008 |
| Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy … RZ Orlowski, A Nagler, P Sonneveld, J Bladé, R Hajek, A Spencer, ... Journal of Clinical Oncology 25 (25), 3892-3901, 2007 | 776 | 2007 |
| Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function T Ponomaryov, A Peled, I Petit, RS Taichman, L Habler, J Sandbank, ... The Journal of clinical investigation 106 (11), 1331-1339, 2000 | 711 | 2000 |
| CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow A Avigdor, P Goichberg, S Shivtiel, A Dar, A Peled, S Samira, O Kollet, ... Blood 103 (8), 2981-2989, 2004 | 638 | 2004 |
| Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients MJ Besser, R Shapira-Frommer, AJ Treves, D Zippel, O Itzhaki, ... Clinical cancer research 16 (9), 2646-2655, 2010 | 630 | 2010 |
| Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk … C Schmid, M Labopin, A Nagler, M Bornhäuser, J Finke, A Fassas, ... Journal of clinical oncology 25 (31), 4938-4945, 2007 | 557 | 2007 |
| Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually JR Passweg, H Baldomero, P Bader, C Bonini, S Cesaro, P Dreger, ... Bone marrow transplantation 51 (6), 786-792, 2016 | 555 | 2016 |
| Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results … P Armand, A Nagler, EA Weller, SM Devine, DE Avigan, YB Chen, ... Journal of clinical oncology 31 (33), 4199, 2013 | 553 | 2013 |
| Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation S Slavin, E Naparstek, A Nagler, A Ackerstein, S Samuel, J Kapelushnik, ... | 537 | 1996 |
| Antilymphocyte globulin for prevention of chronic graft-versus-host disease N Kröger, C Solano, C Wolschke, G Bandini, F Patriarca, M Pini, A Nagler, ... New England Journal of Medicine 374 (1), 43-53, 2016 | 524 | 2016 |
| Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older … M Aoudjhane, M Labopin, NC Gorin, A Shimoni, T Ruutu, HJ Kolb, ... Leukemia 19 (12), 2304-2312, 2005 | 520 | 2005 |
| Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ... Journal of the National Cancer Institute 103 (7), 553-561, 2011 | 517 | 2011 |
| Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease F Locatelli, V Rocha, W Reed, F Bernaudin, M Ertem, S Grafakos, ... Blood, The Journal of the American Society of Hematology 101 (6), 2137-2143, 2003 | 498 | 2003 |
